Jeff Aronin: The Million-dollar Success From The Desire to Find Medical Solutions for Neglected Diseases

It is an unbreakable code in the field of medicine for doctors to first not harm the patient. When there’s a less harmful way to remedy a medical issue, the doctor should resort to that less risky, less invasive and less harmful procedure. This is something that not many physicians seem to put into practice, and so it’s good to know that we still have doctors like Jeff Aronin who live by the code of not doing more harm to the patients than is necessary.


The Fuel That Ignited His Passion


We can read from Gazette Day that the landmark event in the career of Jeff Aronin that fueled his passion for medical research was that one time he had to spare a child a surgery because of a less invasive way of treatment, which is through medicine. It was there, too, that he realized the critical importance of such principle in improving patients’ lives. Besides, it was also the experience that drove him to push for more research on commercialized medicines for unmet medical needs without putting the patient into too much-hidden risk.


After finishing a bachelor’s degree and MBA, Jeff Aronin immediately worked in the healthcare sector. It was there that his desire to develop medicine for unpopular medical needs grew and it was where he finally founded Ovation Pharmaceuticals, of which he is also the CEO. The iteration of Ovation in 2000 was the tipping point of Aronin’s desire to develop medicine for rare and neglected diseases that didn’t receive media coverage. His company also wanted to set itself apart from other big pharma companies that were more interested in getting a blockbuster profit from their research instead of developing medical solutions for areas that need more attention.


The Ultimate Success


Among many successes that Jeff Aronin achieved, it is when Danish healthcare company Lundbeck purchased his Ovation company for $900 million in 2009 that is one of the most remarkable. The company that Jeff Aronin started just from a dream is now valued at more than he could have imagined. After the purchase, Lundbeck still decided to keep Aronin in the company as its CEO, which is an excellent choice because a company’s success highly depends on the visionary and creator behind it.